07:00 , Jun 10, 2013 |  BC Week In Review  |  Clinical News

AZD3965: Phase I started

Cancer Research U.K. began a 2-part, open-label, dose-escalation, U.K. Phase I trial to evaluate 5, 10, 20 and 30 mg oral AZD3965 given once or twice daily in 28-day cycles for up to 6 cycles...
07:00 , Jul 26, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Amyotrophic lateral sclerosis (ALS) Monocarboxylate transporter 1 (MCT1) Mouse and patient sample studies suggest increasing MCT1 levels...
07:00 , Aug 15, 2011 |  BioCentury  |  Product Development

Powering down cancer

The cancer metabolism field has been heating up over the last five years, and now is beginning to produce some of the first data for compounds aimed at stunting aerobic glycolysis, the energy-generating process that...
08:00 , Dec 18, 2008 |  BC Innovations  |  Targets & Mechanisms

Cancer's fuel duel

A team of Belgian and U.S. researchers has demonstrated that hypoxic tumor cells can be killed by targeting solute carrier family 16, member 1 (monocarboxylic acid transporter 1), a membrane lactate transporter protein expressed on...
08:00 , Dec 11, 2008 |  BC Innovations  |  Distillery Therapeutics

This week in therapeutics

The Distillery: Therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer...